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Pyrvinium pamoate (PP) is an FDA-approved classical anthelmintic, but is now attracting
particular attention as an anti-cancer drug after recent ﬁndings of its potent cytotoxicity
against various cancer cell lines only during glucose starvation, as well as its anti-tumor
activity against hypovascular pancreatic cancer cells transplanted in mice. The molec-
ular mechanisms by which PP promotes such preferential toxicity against cancer cells
are currently under extensive investigation. PP suppressed the NADH-fumarate reduc-
tase system that mediates a reverse reaction of the mitochondrial electron-transport chain
complex II in anaerobic organisms such as parasitic helminthes or mammalian cells under
tumor microenvironment-mimicking hypoglycemic/hypoxic conditions, thereby inhibiting
efﬁcient ATP production. PP also inhibited the unfolded protein response induced by glu-
cose starvation, thereby inhibiting the proliferation of pancreatic cancer cells. Even under
normoglycemic/normoxic conditions, PP suppressed the mitochondrial electron-transport
chain complex I and thereby STAT3, inhibiting the proliferation of myeloma/erythroleukemia
cells. Here, we review accumulating knowledge on its working mechanisms and evaluate
PP as a novel anti-cancer drug that targets mitochondrial respiration.
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INTRODUCTION
Cancer cells can adapt to various environments under either
sufﬁcient or insufﬁcient nutrient (glucose)/oxygen conditions,
and are often subjected to the latter because of their excessive
demand for nutrients/oxygen and immature vascularization. For
example, human pancreatic cancer cells in hypovascular tumors
are known to survive under hypoglycemic/hypoxic conditions.
Although ATP is mainly generated by oxidative phosphoryla-
tion in normal cells, this mainly occurs by glycolysis in most
cancer cells, even if oxygen is plentiful, as observed by the
increase in glucose uptake and lactate production (the Warburg
effect; Warburg, 1956). Under hypoxic conditions, the malignant
potential of cancer cells becomes greater (Hockel and Vaupel,
2001) and cancer cells become resistant to some anti-cancer
drugs, includingbleomycin, procarbazine, andvincristine (Teicher
et al., 1981); therefore, a new drug strategy against cancer cells
under such tumor microenvironment-mimicking conditions is
anticipated.
Meanwhile, recent investigations demonstrated that the War-
burg effect may not account for the metabolic diversity that
has been observed among some types of cancer cells (Gog-
vadze et al., 2010; Barbi de Moura et al., 2012; Nakajima and
Van Houten, 2012). The variety of oncogene expression pro-
ﬁles or hypoxia levels may affect tumor evolution and produce
metabolic symbiosis, in which lactate from hypoxic/glycolytic
tumor populations fuels ATP production via oxidative phospho-
rylation in oxygenated regions of the tumor (Nakajima and Van
Houten, 2012). In this context, combination therapy with one
drug for hypoxic/glycolytic tumors and another for oxygenated
tumors (where oxidative phosphorylation is activated) may be
more favorable than monotherapy.
Because some parasites have the ability to produce ATP
under anaerobic conditions through speciﬁc metabolic pathways,
these mechanisms have often been the target of anthelmintics.
Pyrvinium (6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenylpy-
rrol-3-yl)ethenyl]-1-methyl-quinolinium) pamoate (PP) is a clas-
sical anthelmintic that has been popular under the marketing
name of Povan (Parke–Davis) orVanquin (Pﬁzer; Most, 1972). PP
is a cyanine dye that has been used to treat pinworm infection as
well as strongyloidiasis in humans (Downey et al., 2008), receiving
FDA approval for treatment of enterobiasis in 1955 (NDA-9582).
The usual human dosage is 5 mg/kg/day, up to 350 mg, but PP
has been used safely at doses as high as 35 mg/kg/day for 3–5 days.
The drug has no measurable absorption across the gastrointesti-
nal tract, and ∼90% is excreted in feces (Smith et al., 1976). PP
has been replaced generally by more effective, broad-spectrum
anthelmintics; it has been discontinued in the United States, but is
still available under the Parke–Davis label in Europe or under the
name Pamoxan (Sato Pharmaceutical, Tokyo) in Japan. In 2004,
Esumi and colleagues ﬁrst demonstrated the potent cytotoxic abil-
ity of PP against humanpancreatic cancer cells only during glucose
starvation, shedding new light on its potential as an anti-cancer
drug (Esumi et al., 2004).
ANTI-CANCER EFFECTS OF PP VIA COMPLEX II UNDER
HYPOGLYCEMIC/HYPOXIC CONDITIONS
Esumi et al. (2004) found that PP exerts cytotoxic activity against
PANC-1 human pancreatic cancer cells in glucose-deprived
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medium, but not in glucose-supplemented medium; such pref-
erential cytotoxicity was also observed in other human pancreatic
cancer cell lines (Capan-1 and KP-3) as well as a human colon
cancer cell line (WiDr)). PP potently inhibited the growth of
WiDr cells in the spheroid form that mimics the structural orga-
nization of tumor tissue where the supply of glucose/oxygen is
limited, and inhibited the Akt-Ser473 phosphorylation induced by
glucose starvation in PANC-1 cells that is essential for their sur-
vival (Esumi et al., 2004). Moreover, oral administration of PP
prevented the tumor growth and Akt-Ser473 phosphorylation of
PANC-1 cells subcutaneously transplanted into nude and severe
combined immunodeﬁciency (SCID) mice (Esumi et al., 2004).
As mechanisms by which these pancreatic cells survived
under hypoglycemic conditions and PP showed such pref-
erential toxicity, they proposed the NADH-fumarate reduc-
tase (FRD) system (Figure 1; Tomitsuka et al., 2010). In the
mammalian mitochondrial electron-transport chain under nor-
mal aerobic conditions, electrons from NADH are transferred to
complex I (NADH-ubiquinone reductase: EC 1.6.2.3), complex III
FIGURE 1 | Effects of PP on the mitochondrial electron-transport chain
under aerobic or anaerobic conditions. (A) In mammals under normal
aerobic conditions, PP inhibits complex I but activates complex II SQR
activity, thereby maintaining cellular respiration and ATP production. (B) In
parasites or mammals under anaerobic conditions, the NADH-fumarate
reductase system maintains ATP production with no need of oxygen by
only using proton gradients via complex I. PP inhibits both complex I and
complex II FRD activity, thereby showing potent inhibition of ATP
production.
(ubiquinol-cytochrome c reductase: EC 1.10.2.2), and then com-
plex IV (cytochrome c oxidase: EC1.9.3.1), or those from succinate
are transferred to complex II (succinate-ubiquinone reductase
(SQR), which converts succinate into fumarate: EC 1.3.5.1), com-
plex III, and then complex IV (Figure 1A). Complex IV mediates
the oxidation of cytochrome c as well as the reduction of O2 to
H2O (cellular respiration) via the transport of four electrons, and
complexes I, III, and IV function as proton pumps to produce pro-
ton gradients across the inner mitochondrial membrane, driving
ATP synthase (EC 3.6.3.14) for energy production (Figure 1A).
In anaerobic organisms, electrons from NADH are transferred to
complex I, and then NADH-FRD (EC 1.3.1.6), which mediates
the reverse reaction of complex II by converting fumarate to suc-
cinate (Figure 1B). In this system, only complex I functions as a
proton pump with no need for oxygen and amino acids could be
used as an energy source instead of glucose (Figure 1B; Tomitsuka
et al., 2010).
While the presence of this system in mammals is uncertain,
relatively low but distinct FRD activities have been detected in
mitochondrial fractions of six cancer cell lines (DLD-1, HT-29,
PSN-1, Capan-1, PANC-1, and HepG2; Tomitsuka et al., 2009).
The FRD/SQR activity ratios in mitochondrial fractions of these
cell lines were much lower than in Ascaris suum, a parasitic nema-
tode; however, the ratio in DLD-1 mitochondria was regulated
by in vitro phosphorylation (i.e., increased by the treatment of
phosphatase and decreased by that of protein kinase A) and those
in mitochondrial fractions of DLD-1, PANC-1, and HepG2 were
increased after culture for a few days under hypoglycemic/hypoxic
conditions (Tomitsuka et al., 2009, 2012). PP was shown to inhibit
FRD activity in both parasites and mammalian mitochondria
and to increase SQR activity in human cancer cell lines under
normal culture conditions but not under hypoglycemic/hypoxic
conditions, while inhibiting complex I to some extent under
either condition (Figure 1; Tomitsuka et al., 2012). The precise
molecular mechanisms of the effects of PP remain unclear, but
PP may inﬂuence the phosphorylation status of the ﬂavoprotein
subunit in complex II through the activation of mitochondrial
phosphatase(s) (Tomitsuka et al., 2012).
ANTI-CANCER EFFECTS OF PP VIA COMPLEX I AGAINST
MYELOMA/ERYTHROLEUKEMIA CELLS
We recently found that PP is also effective against myeloma/eryth-
roleukemia cells under normoglycemic/normoxic conditions; it
potently inhibited the proliferation of human myeloma (U266B1
and PCM6) and erythroleukemia (HEL 92.1.7) cell lines (Harada
et al., 2012). IL-6 is known to induce STAT3-Tyr705 phosphoryla-
tion by JAKs, especially JAK2, in the two myeloma cells, and HEL
92.1.7 cells have a constitutively active JAK2(V617F) mutation
and thus a constitutively activated (Tyr705-phosphorylated) STAT3
without IL-6; PP also potently inhibited both IL6-dependent and
constitutive STAT3-Tyr705 phosphorylation (Harada et al., 2012).
PP inhibitedmitochondrial electron-transport chain complex I, as
evidenced by its inhibition of cellularATP production andO2 con-
sumption of all three cells, its inhibition of speciﬁc complex I activ-
ity inmouse kidneymitochondria-rich fractions, and the complete
absence of its inhibitory effects on ATP production/cell prolifer-
ation in mitochondrial respiration-deﬁcient HEL 92.1.7-ρ0 cells.
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FIGURE 2 | Proposed mechanisms of inhibitory effects of PP on the
proliferation of myeloma/erythroleukemia cells. IL-6 binds to its
transmembrane receptor (IL-6R) and activates JAK2, which phosphorylates
STAT3. Tyr705-phosphorylated STAT3 (P-STAT3) translocates to the nucleus
and activates transcription of Bcl-XL, Bcl-2, and cyclin D1, thereby inhibiting
apoptosis and inducing cell cycle progression of myeloma/erythroleukemia
cells. PP inhibits mitochondrial electron-transport chain complex I and
activates AMPK to inhibit STAT3-Tyr705 phosphorylation (Harada et al.,
2012).
Rotenone and antimycinA potently inhibited STAT3-Tyr705 phos-
phorylation in all three cells and their effects were absent in HEL
92.1.7-ρ0 cells. Taken together, PP impaired mitochondrial com-
plex I and thereby inhibited STAT3 activation, leading to the sup-
pression of cancer cell growth, as schematized in Figure 2 (Harada
et al., 2012).
Pyrvinium pamoate as well as rotenone/antimycin A can acti-
vate AMP-activated protein kinase (AMPK; Hayashi et al., 2000;
Wang et al., 2003; Harada et al., unpublished observation), which
inhibits STAT3-Tyr705 phosphorylation (Nerstedt et al., 2010);
therefore, AMPK may link the mitochondrial electron-transport
chain and STAT3, although it is intriguing that AMPK may para-
doxically play a critical role in the tolerance of cancer cells to
nutrient deprivation (Kato et al., 2002). The protein interaction
between mitochondrial (not nuclear) STAT3 and mitochondrial
electron-transport chain complexes, especially complex I/II, has
been proposed (Wegrzyn et al., 2009), although a stoichiometric
study suggests that direct protein interaction is not required for
optimal ATP production, nor can it markedly modulate oxida-
tive phosphorylation in vivo (Phillips et al., 2010). Furthermore,
PP may interact with gene associated with retinoid-interferon-
induced mortality 19 (GRIM-19), a component of the mitochon-
drial electron-transport chain complex I that inhibits STAT3 to
induce pro-apoptotic gene expression and thereby apoptosis of
cancer cells (Kalvakolanu et al., 2010). Because constitutively active
STAT3 up-regulates anti-apoptotic genes to promote tumor sur-
vival, its inhibition by GRIM-19 demonstrates an anti-oncogenic
effect exerted by biological therapeutics (Zhang et al., 2003). The
PP signaling pathway leading to STAT3 inhibition awaits further
investigation.
OTHER EFFECTS OF PP AGAINST CANCER CELLS
Unfolded protein response (UPR) is a cellular stress response
induced by the accumulation of unfolded or misfolded proteins
in the lumen of the endoplasmic reticulum (Liu and Kaufman,
2003); UPR is known to be induced by glucose starvation and
hypoxia. The UPR has two primary aims: initially to restore nor-
mal function of the cell by halting protein translation and to
activate the signaling pathways that lead to increasedproductionof
molecular chaperones involved in proper protein folding. Yu et al.
(2008) found that PP inhibited the glucose starvation-induced
transcriptional activation of several UPR target genes, including
glucose-regulated protein 78 (GRP78), GRP94, XBP-1, and ATF4,
in PANC-1 cells, and the ectopic over-expression of GRP78 in
PANC-1 cells partially prevented the inhibitory effect of PP on its
proliferation. Themechanism by which PP regulates transcription
remains unknown.
Another study identiﬁed PP as a potent inhibitor of Wnt sig-
naling in a chemical screening for small molecules that stabilize
β-catenin and inhibit Axin degradation (Thorne et al., 2010). PP
was found to bind to all types of mammalian casein kinase 1 (CK1)
isoforms (α, γ1–3, δ, and ε) that are implicated in Wnt signaling,
but to activate onlyCK1α (Thorne et al., 2010; Zelenak et al., 2012).
PP treatment of colon cancer cells with mutation of adenomatous
polyposis coli (APC) and β-catenin inhibited both Wnt signaling
and proliferation (Thorne et al., 2010).
Pyrvinium pamoate was also found to act as a non-competitive
androgen receptor (AR) inhibitor; PP inhibited endogenous AR
activity in two prostate cancer cell lines, LANCaP and LAPC4, and
reduced the expression of several androgen-responsive genes in
LANCaP cells (Jones et al., 2009). PP does not have a chemical
structure similar to known AR ligands or compete with them in
AR binding. Although the direct target of PP remains unknown,
PP may bind to AR and prevent its normal conformation change,
or interfere with the assembly of a productive AR-transcription
initiation complex (Jones et al., 2009).
COMBINATION THERAPY WITH OTHER ANTI-CANCER
DRUGS
We found that PP acts synergistically with dexamethasone, the
ﬁrst choice drug for various types of myeloma, to inhibit the pro-
liferation of human myeloma PCM6 cells; the 50% inhibitory
concentration of dexamethasone is 100 μM in the absence of PP
but is 25μMin the presence of 1 nMPP (Harada et al., 2012). Dex-
amethasone is themost effective single agent formultiplemyeloma
when given in high doses, although the risk of various side effects
unique to steroids (e.g., weight gain, diabetes, infection, mood
swings, and gastrointestinal problems) is much higher at these
doses. The sites of actions were different between PP and dex-
amethasone (Harada et al., 2012), and their combination may be
beneﬁcial to avoid such side effects of steroids.
Furthermore, Yu et al. (2008) reported that combination ther-
apy with doxorubicin effectively reduces the size of PC3 tumor
xenografts in athymic mice; PP (p.o. 10 mg/kg, six times/week)
in combination with doxorubicin (i.p. 4 mg/kg, weekly for
2 weeks) markedly reduced their size (∼20% volume of non-
treated) when each monotherapy had no effect. Doxorubicin is
a DNA-intercalating anthracycline antibiotic that is widely used
against various types of cancers, including some leukemia, mul-
tiple myeloma, and cancers of the bladder, breast, stomach, lung,
ovaries, thyroid, soft tissue sarcoma, and others. Its combination
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with PP may ameliorate its adverse effects, such as nausea, vom-
iting, arrhythmia, and typhlitis. Such combinational usage with
other anti-cancer drugs may be practical and beneﬁcial because
the safety of PP has been proven.
CONCLUSION
Several recent investigations have highlighted PP as a novel type
of anti-cancer drug; it may suppress mitochondrial electron-
transport chain complex II under tumor microenvironment-
mimicking hypoglycemic/hypoxic conditions or complex I/STAT3
under normoglycemic/normoxic conditions, thereby inhibiting
the growth of various cancer cell types. Furthermore, PP may
inﬂuence several signaling pathways, including UPR, Wnt, and
AR, to inhibit cancer cell proliferation, although the underlying
molecular mechanisms await further investigation. Because PP
has some difﬁculties in solubility and absorption across the gas-
trointestinal tract, the development of other soluble pyrvinium
salts and structural mimetics is anticipated.
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